Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED90 of Remimazolam for Sedation Maintenance
NCT05379777Phase 4Completed
- Sponsor
- Asan Medical Center
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam in sedation, sponsored by Asan Medical Center. Primary endpoint: Success or failure of sedation maintenance. Started May 2022; status: completed.
02
Drugs
remimazolam
03
Conditions
sedation
Beyond the preview
Go deeper on NCT05379777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05379777.